Molecule
IL-4
Type 2 master cytokine
- Expression change
- Elevated
- Evidence level
- established
- Targeted by
- Dupilumab (via IL-4Rα blockade)
Role in pathogenesis
IL-4 drives B-cell class switching to IgE, promotes Th2 differentiation, and upregulates VCAM-1 for eosinophil recruitment. Signals through IL-4Rα/JAK1/STAT6. Dupilumab blocks IL-4 signalling by targeting IL-4Rα.
Targeting drugs (1)
| Drug | Mechanism | Response rate | Line |
|---|---|---|---|
| Dupilumab | Anti–IL-4Rα monoclonal antibody (blocks IL-4 and IL-13) | ~75% polyp reduction | 1st-line biologic |